Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers

Molecular Therapy Nucleic Acids

Volumn 4, Issue 4, 2015, Pages e237-

  Prodeus, Aaron ^a,b   Abdul Wahid, Aws ^b   Fischer, Nicholas W ^a,b   Huang, Eric H B ^b   Cydzik, Marzena ^b   Gariépy, Jean ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Canada   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; DNA aptamer; Immunotherapy; PD 1

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APTAMER; APTAMER MP5; APTAMER MP7; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISSEMINATED CANCER; DISSOCIATION CONSTANT; EXTRACELLULAR MATRIX; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHELF LIFE; T LYMPHOCYTE; TUMOR ESCAPE;

EID: 84940211893     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.11     Document Type: Article

References (42)

1. Drake, CG, Jaffee, E and Pardoll, DM (2006). Mechanisms of immune evasion by tumors. Adv Immunol 90: 51-81.
2. Ceeraz, S, Nowak, EC and Noelle, RJ (2013). B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 34: 556-563.
3. Yaddanapudi, K, Mitchell, RA and Eaton, JW (2013). Cancer vaccines: Looking to the future. Oncoimmunology 2: e23403.
4. Freeman, GJ, Long, AJ, Iwai, Y, Bourque, K, Chernova, T, Nishimura, H et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034.
5. Latchman, Y, Wood, CR, Chernova, T, Chaudhary, D, Borde, M, Chernova, I et al. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261-268.
6. Francisco, LM, Sage, PT and Sharpe, AH (2010). The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236: 219-242.
7. Dong, H, Strome, SE, Salomao, DR, Tamura, H, Hirano, F, Flies, DB et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
8. Yokosuka, T, Takamatsu, M, Kobayashi-Imanishi, W, Hashimoto-Tane, A, Azuma, M and Saito, T (2012). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 209: 1201-1217.
9. Sanmamed, MF and Chen, L (2014). Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 20: 256-261.
10. Dong, H, Zhu, G, Tamada, K and Chen, L (1999). B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365-1369.
11. Azuma, T, Yao, S, Zhu, G, Flies, AS, Flies, SJ and Chen, L (2008). B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-3643.
12. Hirano, F, Kaneko, K, Tamura, H, Dong, H, Wang, S, Ichikawa, M et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089-1096.
13. Callahan, MK and Wolchok, JD (2013). At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 94: 41-53.
14. Hamid, O, Robert, C, Daud, A, Hodi, FS, Hwu, WJ, Kefford, R et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144.
15. Topalian, SL, Hodi, FS, Brahmer, JR, Gettinger, SN, Smith, DC, McDermott, DF et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
16. Harding, FA, Stickler, MM, Razo, J and DuBridge, RB (2010). The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2: 256-265.
17. Nelson, AL, Dhimolea, E and Reichert, JM (2010). Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9: 767-774.
18. Chames, P, Van Regenmortel, M, Weiss, E and Baty, D (2009). Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157: 220-233.
19. Keefe, AD, Pai, S and Ellington, A (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
20. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
21. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
22. White, RR, Sullenger, BA and Rusconi, CP (2000). Developing aptamers into therapeutics. J Clin Invest 106: 929-934.
23. Eyetech Study Group. (2003) Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmol 110: 979-986.
24. Eyetech Study Group. (2002) Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22: 143-152.
25. Lázár-Molnár, E, Yan, Q, Cao, E, Ramagopal, U, Nathenson, SG and Almo, SC (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci USA 105: 10483-10488.
26. Cheng, X, Veverka, V, Radhakrishnan, A, Waters, LC, Muskett, FW, Morgan, SH et al. (2013). Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 288: 11771-11785.
27. Da Pieve, C, Blackshaw, E, Missailidis, S and Perkins, AC (2012). PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice. Bioconjug Chem 23: 1377-1381.
28. Healy, JM, Lewis, SD, Kurz, M, Boomer, RM, Thompson, KM, Wilson, C et al. (2004). Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21: 2234-2246.
29. Terawaki, S, Chikuma, S, Shibayama, S, Hayashi, T, Yoshida, T, Okazaki, T et al. (2011). IFN-á directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186: 2772-2779.
30. Orava, EW, Abdul-Wahid, A, Huang, EH, Mallick, AI and Gariépy, J (2013). Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen. Mol Oncol 7: 799-811.
31. Krieg, AM (2002). CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760.
32. Krug, A, Rothenfusser, S, Hornung, V, Jahrsdorfer, B, Blackwell, S, Ballas, ZK et al. (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31: 2154-2163.
33. Santulli-Marotto, S, Nair, SK, Rusconi, C, Sullenger, B and Gilboa, E (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 63: 7483-7489.
34. McNamara, JO, Kolonias, D, Pastor, F, Mittler, RS, Chen, L, Giangrande, PH et al. (2008). Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 118: 376-386.
35. Pastor, F, Soldevilla, MM, Villanueva, H, Kolonias, D, Inoges, S, de Cerio, AL et al (2013). CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids 2: e98.
36. Orava, EW, Jarvik, N, Shek, YL, Sidhu, SS and Gariépy, J (2013). A short DNA aptamer that recognizes TNFá and blocks its activity in vitro. ACS Chem Biol 8: 170-178.
37. Prodeus, A, Cydzik, M, Abdul-Wahid, A, Huang, E, Khatri, I, Gorczynski, R et al. (2014). Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival. Mol Ther Nucleic Acids 3: e190.
38. Abdul-Wahid, A, Huang, EH, Lu, H, Flanagan, J, Mallick, AI and Gariépy, J (2012). A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo. Int J Cancer 131: 2839-2851.
39. Alam, KK, Chang, JL and Burke, DH (2015). FASTAptamer: A Bioinformatic Toolkit for High-throughput Sequence Analysis of Combinatorial Selections. Mol Ther Nucleic Acids 4: e230.
40. Zuker, M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
41. Lazar-Molnar, E, Ramagopal, UA, Nathenson, SG, Almo, SC. (2011). Crystal structure of the extracellular domain of human PD-1.
42. Zhang, X, Schwartz, JC, Guo, X, Bhatia, S, Cao, E, Lorenz, M et al. (2004). Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20: 337-347.